Table 4

Association of time-varying platelet count with time to VTE in individuals with and without immune-mediated inflammatory diseases (IMID) in adjusted and multivariable analysis

Without IMID
n=160 969, VTE events=3250
n=51 389, VTE events=1417
HR (95% CI)
HR (95% CI)
HR (95% CI)
HR (95% CI)
Low (<150×109/L)1.88 (1.60–2.20)1.06 (0.98–1.14)1.62 (1.23–2.12)1.24 (0.94–1.62)
Normal (150–400×109/L)1.00 (ref)1.00 (ref)1.00 (ref)1.00 (ref)
High (>400×109/L)*2.13 (1.83–2.43)1.98 (1.73–2.26)1.59 (1.35–1.87)1.72 (1.46–2.03)
  • *Adjusted for age, sex, index of multiple deprivation quintile, ethnicity, body mass index category, smoking status, alcohol category, hypertension, hyperlipidaemia, type 2 diabetes, peripheral arterial disease, atrial fibrillation, myocardial infarction, stroke, heart failure, Chronic kidney disease stage 3–5, Chronic obstructive pulmonary disease, chronic liver disease, malignancy, reduced mobility, use of medication (NSAIDs, antiplatelets, warfarin, DOACs, hormone replacement therapy, oestrogen contraceptives, immunotherapy, corticosteroids and statins).

  • Individuals with at least one valid platelet measure over the study period included.

  • DOAC, direct oral anticoagulants; ,NSAID non-steroidal anti-inflammatory drug.